Jazz Pharmaceuticals Touts Record $4.3B 2025 Revenue, Reaffirms 2026 Outlook at Conference [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives highlighted record 2025 revenue, a growing pipeline anchored by oncology programs, and a refined strategy emphasizing rare diseases during a conference session featuring Chief Financial Officer Philip Johnson and investor relations leaders Jack Spinks and John Bluth. 2025 results and 2026 outlook Johnson said 2025 marked “our 21st consecutive year of top-line revenue growth,” driven by “strong commercial execution across our diversified portfolio” that delivered record total revenue of $4.3 billion. Looking ahead, he reiterated the company's previously issued 2026 guidance, calling for total revenue of $4.25 billion to $4.5 billion as Jazz seeks a 22nd consecutive year of growth. ? 5 Space Stocks Already Climbing Ahead of the SpaceX IPO Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game) Within that outlook, Johnson said Jazz expects double-digit growth in its epilepsy and oncology franc
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Strong Recent Returns And Oncology Pipeline Focus [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (JAZZ) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Jazz Pharmaceuticals (JAZZ) was upgraded by Raymond James Financial, Inc. to "moderate buy".MarketBeat
- Jazz Pharmaceuticals (JAZZ) was given a new $227.00 price target by Raymond James Financial, Inc..MarketBeat
- Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual MeetingPR Newswire
JAZZ
Earnings
- 2/24/26 - Beat
JAZZ
Sec Filings
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- 3/27/26 - Form SCHEDULE
- JAZZ's page on the SEC website